tradingkey.logo

Insulet Corp

PODD
查看詳細走勢圖
289.620USD
-3.260-1.11%
收盤 12/19, 16:00美東報價延遲15分鐘
20.37B總市值
82.66本益比TTM

Insulet Corp

289.620
-3.260-1.11%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.11%

5天

-2.06%

1月

-16.38%

6月

-4.03%

今年開始到現在

+10.94%

1年

+12.89%

查看詳細走勢圖

TradingKey Insulet Corp股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Insulet Corp當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名42/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價378.05。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Insulet Corp評分

相關信息

行業排名
42 / 208
全市場排名
120 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 27 分析師
買入
評級
378.047
目標均價
+27.64%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Insulet Corp亮點

亮點風險
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
業績高增長
公司營業收入穩步增長,連續3年增長58.71%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入2.07B美元
估值合理
公司最新PE估值82.66,處於3年歷史合理位
機構減倉
最新機構持股72.07M股,環比減少4.83%
Mairs and Power 公司持倉
明星投資者Mairs and Power 公司持倉,最新持倉1.13K股

Insulet Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Insulet Corp簡介

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
公司代碼PODD
公司Insulet Corp
CEOMcevoy (Ashley)
網址https://www.omnipod.com

常見問題

Insulet Corp(PODD)的當前股價是多少?

Insulet Corp(PODD)的當前股價是 289.620。

Insulet Corp 的股票代碼是什麼?

Insulet Corp的股票代碼是PODD。

Insulet Corp股票的52週最高點是多少?

Insulet Corp股票的52週最高點是354.880。

Insulet Corp股票的52週最低點是多少?

Insulet Corp股票的52週最低點是230.050。

Insulet Corp的市值是多少?

Insulet Corp的市值是20.37B。

Insulet Corp的淨利潤是多少?

Insulet Corp的淨利潤為418.30M。

現在Insulet Corp(PODD)的股票是買入、持有還是賣出?

根據分析師評級,Insulet Corp(PODD)的總體評級為買入,目標價格為378.047。

Insulet Corp(PODD)股票的每股收益(EPS TTM)是多少

Insulet Corp(PODD)股票的每股收益(EPS TTM)是3.504。
KeyAI